The 219133 monoclonal antibody specifically recognizes C-type lectin-like receptor 2 (CLEC-2). CLEC-2 is a ~32 kDa type II transmembrane glycoprotein that is encoded by CLEC1B (C-type lectin domain family 1 member B). CLEC-2 (CLEC1B) is expressed on platelets, megakaryocytes, and myeloid cells. The extracellular domain of this molecule contains a single carbohydrate recognition domain (CRD), whereas the cytoplasmic region contains a YXXL amino acid signaling motif which is also known as a hem-immunoreceptor tyrosine-based activation motif (hemITAM). Podoplanin binding to CLEC-2 (CLEC1B) leads to the transduction of tyrosine kinase signaling that can play roles in the activation and aggregation of platelets, tumor metastasis, or the formation of lymphatic vessels. CLEC-2 (CLEC1B) also serves as a receptor for the rhodocytin, a platelet-aggregating snake venom protein, or as a co-receptor for the attachment human immunodeficiency virus type 1 (HIV-1).
The antibody was conjugated to BD Horizon BUV615 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 615 nm. BD Horizon Brilliant BUV615 can be excited by the ultraviolet laser (355 nm) and detected with a 610/20 filter and a 595 nm LP. Due to the excitation of the acceptor dye by the blue/yellow-green laser line, there may be significant spillover into channels detecting PE-CF594 like emissions (eg, 610/20-nm filter).